This is the repository of data and scripts for the analysis of the CellminerCDB-SCLC manuscript and website (https://discover.nci.nih.gov/SclcCellMinerCDB/) CellMiner-SCLC (https://discover.nci.nih.gov/SclcCellMinerCDB) integrates 118 patient-derived cell lines with drug sensitivity and genomic datasets, including high resolution methylome and RNAseq data. CellMiner-SCLC provides a new resource for SCLC research for this “recalcitrant cancer”. Of fundamental importance, we demonstrate the reproducibility and stability of the cell line datasets from different institutions (CCLE, GDSC, CTRP, NCI and UTSW). We validate the classification based on four master transcription factors: NEUROD1, ASCL1, POU2F3 and YAP1 and show transcription networks connecting them with the MYC genes (MYC, MYCL1 and MYCN) and the NOTCH and HIPPO pathways. We find that the 4 subsets express specific surface markers for antibody-targeted therapies. The YAP1-driven (SCLC-Y) cell lines differ from the other subsets by expressing the NOTCH pathway, epithelial-mesenchymal-transition (EMT) and antigen-presenting machinery (APM) genes, and by responding to mTOR and AKT inhibitors, suggesting the potential of NOTCH modulators, YAP1 inhibitors and immune checkpoint inhibitors for SCLC-Y tumors.